Azione ALA AROVELLA THERAPEUTICS LIMITED
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Arovella Therapeutics Limited

Azioni

ALA

AU0000182784

Mercato chiuso - Australian S.E.
Altri mercati azionari
 08:10:55 23/04/2024 		Variaz. 5gg Var. 1 gen.
0,12 AUD +4,35% Grafico intraday di Arovella Therapeutics Limited +14,29% +4,35%
26/03 Arovella Therapeutics riceve impegni fermi per una raccolta di circa 12,5 milioni di dollari australiani MT
20/03 La collaborazione di Arovella Therapeutics con Imugene su ALA-101-onCARlytics termina; le azioni scendono del 12%. MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%
Arovella Therapeutics Ltd. Announces Change of Company Address
Arovella Therapeutics Appoints CFO
Arovella Therapeutics Limited Announces Changes to its Board
Arovella Therapeutics Limited Announces Executive Changes
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan
Arovella Therapeutics Extends Closing Date of Share Purchase Plan
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance
Arovella Therapeutics focused on driving ALA-101 into the clinic
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan
Arovella Therapeutics progresses patient-focused iNKT vision
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione ALA
  4. Notizie Arovella Therapeutics Limited
  5. Altre lingue